Biosense Webster Launches Optrell Mapping Catheter With Trueref Technology for Mapping of Complex Cardiac Arrhythmias

July 24, 2023—Biosense Webster, Inc., part of Johnson & Johnson MedTech, announced the United States launch of the Optrell mapping catheter with the company’s Trueref technology powered by the Carto 3 system. The Optrell with Trueref received FDA 510(k) clearance in 2022. The company advised that Optrell with Trueref will be commercially available in Japan later this year.

According to the company, Optrell is a high-density diagnostic catheter with small electrodes arranged in a fixed-array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.

The catheter’s 48 electrodes are symmetrically distributed across and along six splines, and the catheter combines with the Carto 3 system to deliver information and high-resolution directional mapping.

Additionally, the device’s tight electrode spacing and small electrodes produce higher signal resolution, resulting in enhanced maps of the heart. These high-definition maps provide clinicians with a better understanding of where the arrhythmia is occurring so they can develop a more effective ablation strategy.

BioSense Webster’s Carto 3 system features local conduction vectors that display the real-time direction and speed of the electrical impulses traveling through the heart, providing clinicians with an enhanced understanding of complex circuits and mechanisms and the ability to detect gaps in ablation lesions, advised the company.

“The Optrell mapping catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets,” commented Pasquale Santangeli, MD. “This catheter and the local conduction vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AFib, redo AFib ablation, atrial tachycardia, and ventricular tachycardia.”

Dr. Santangeli is with the Department of Cardiovascular Medicine at the Cleveland Clinic Main Campus in Cleveland, Ohio.